The Role of the Immune Response in Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries; with the aging population, the negative health impacts and costs of the disease will increase dramatically over the next decade. Although the exact cause of AMD is unknown, genetic studies have implicated the complement system as well as other immune responses in disease pathogenesis and severity. Furthermore, histologic studies have shown the presence of macrophages, lymphocytes, and mast cells, as well as fibroblasts, in both atrophic lesions and with retinal neovascularization. This review summarizes discussions from the fifth annual conference of the Arnold and Mabel Beckman Initiative for Macular Research by the Inflammation and Immune Response Task Force. These deliberations focused on the role of inflammatory immune responses, including complement, inflammasomes, adaptive immune responses, and para-inflammation, unanswered questions and studies to address these questions, and potential immune-related therapeutic targets for AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 2×
“Medzhitov first introduced the idea of para-inflammation as a tissue adaptive response to noxious stress or malfunction that has characteristics intermediate between basal and inflammatory states [10].”
BackgroundComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Shi, C.-S., Shenderov, K., Huang, N.-N., Kabat, J., Abu-Asab, M., Fitzgerald, K. A., Sher, A., & Kehrl, J. H. (2012) · Nature Immunology · doi:10.1038/ni.2215 · Cited by 1,367
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265
Microglial cell origin and phenotypes in health and disease
Saijo, K., & Glass, C. K. (2011) · Nature Reviews Immunology · doi:10.1038/nri3086 · Cited by 1,100 · cited 1×
“The tissue consequence of microglial activation is context dependent [6, 7].”
BackgroundA role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
The inflammasome: an integrated view
Gross, O., Thomas, C. J., Guarda, G., & Tschopp, J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01046.x · Cited by 778 · cited 1×
“Once activated, caspase-1 cleaves the inactive precursors of two proinflammatory cytokines, interleukin 1β (IL-1β) and IL18, thereby generating mature forms which are then secreted from cells [69].”
BackgroundAnderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
Oxidative damage-induced inflammation initiates age-related macular degeneration
Hollyfield, J. G., Bonilha, V. L., Rayborn, M. E., Yang, X., Shadrach, K. G., Lu, L., Ufret, R. L., Salomon, R. G., & Perez, V. L. (2008) · Nature Medicine · doi:10.1038/nm1709 · Cited by 710
Para-Inflammation in the Aging Retina
Xu, H., Chen, M., & Forrester, J. V. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.06.001 · Cited by 659 · cited 1×
“, the macula), has also been postulated to contribute to the development of AMD [11].”
BackgroundDrusen complement components C3a and C5a promote choroidal neovascularization
Nozaki, M., Raisler, B. J., Sakurai, E., Sarma, J. V., Barnum, S. R., Lambris, J. D., Chen, Y., Zhang, K., Ambati, B. K., Baffi, J. Z., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408835103 · Cited by 650
Maller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D., Daly, M. J., & Seddon, J. M. (2006) · Nature Genetics · doi:10.1038/ng1873 · Cited by 599 · cited 1×
“Multiple other CFH variants, both common and rare, influence risk of developing AMD [18, 20, 21, 53–55].”
BackgroundDICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88
Tarallo, V., Hirano, Y., Gelfand, B. D., Dridi, S., Kerur, N., Kim, Y., Cho, W. G., Kaneko, H., Fowler, B. J., Bogdanovich, S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.036 · Cited by 592 · cited 1×
“disorders; its activity has also been implicated in diseases such as Alzheimer’s disease, cancer, type II diabetes, and most recently AMD [71, 73, 74].”
BackgroundImmunological and Aetiological Aspects of Macular Degeneration
Penfold, P. L., Madigan, M. C., Gillies, M. C., & Provis, J. M. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00025-2 · Cited by 460 · cited 1×
“Although patients with AMD do not have signs of overt ocular inflammation, histologic studies have shown the presence of macrophages, lymphocytes, and mast cells, as well as fibroblasts, associated with both atrophic lesions and with neovascularization of the retina [3].”
BackgroundVariation in complement factor 3 is associated with risk of age-related macular degeneration
Maller, J. B., Fagerness, J. A., Reynolds, R. C., Neale, B. M., Daly, M. J., & Seddon, J. M. (2007) · Nature Genetics · doi:10.1038/ng2131 · Cited by 437 · cited 1×
“In addition to risk and protective variants of CFH and CFH-related genes, polymorphisms in AP components C3 [57, 58] and factor B [30, 58] are also associated with AMD.”
BackgroundVariation near complement factor I is associated with risk of advanced AMD
Fagerness, J. A., Maller, J. B., Neale, B. M., Reynolds, R. C., Daly, M. J., & Seddon, J. M. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.140 · Cited by 357
Seddon, J. M. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.6.774 · Cited by 354
Despriet, D. D. G., Klaver, C. C. W., Witteman, J. C. M., Bergen, A. A. B., Kardys, I., de Maat, M. P. M., Boekhoorn, S. S., Vingerling, J. R., Hofman, A., Oostra, B. A., et al. (2006) · JAMA · doi:10.1001/jama.296.3.301 · Cited by 348 · cited 1×
“Multiple outstanding reports have detailed and reviewed this evidence at the genetic, RNA and protein levels [13, 14, 16–25].”
BackgroundA rare penetrant mutation in CFH confers high risk of age-related macular degeneration
Raychaudhuri, S., Iartchouk, O., Chin, K., Tan, P. L., Tai, A. K., Ripke, S., Gowrisankar, S., Vemuri, S., Montgomery, K., Yu, Y., et al. (2011) · Nature Genetics · doi:10.1038/ng.976 · Cited by 323 · cited 2×
“In contrast, a rare and defective CFH variant confers substantial risk (with high penetrance) for AMD [12].”
BackgroundReynolds, R., Hartnett, M. E., Atkinson, J. P., Giclas, P. C., Rosner, B., & Seddon, J. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3928 · Cited by 294
Self-citationSeddon, J. M., Reynolds, R., Maller, J., Fagerness, J. A., Daly, M. J., & Rosner, B. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3064 · Cited by 285
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein
Laine, M., Jarva, H., Seitsonen, S., Haapasalo, K., Lehtinen, M. J., Lindeman, N., Anderson, D. H., Johnson, P. T., Järvelä, I., Jokiranta, T. S., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3831 · Cited by 246
Johnson, P. T., Betts, K. E., Radeke, M. J., Hageman, G. S., Anderson, D. H., & Johnson, L. V. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606234103 · Cited by 223
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205 · cited 1×
“Importantly, in each model evaluated, complement activation amplifies the generation of vascular endothelial growth factor (VEGF), which is strongly implicated in fueling the development of CNV and AMD [68].”
BackgroundSepp, T., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Moore, A. T., Bird, A. C., & Yates, J. R. W. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1143 · Cited by 186
Clark, S. J., Higman, V. A., Mulloy, B., Perkins, S. J., Lea, S. M., Sim, R. B., & Day, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605083200 · Cited by 185
Hypomethylation of the IL17RC Promoter Associates with Age-Related Macular Degeneration
Wei, L., Liu, B., Tuo, J., Shen, D., Chen, P., Li, Z., Liu, X., Ni, J., Dagur, P., Sen, H. N., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.013 · Cited by 167 · cited 1×
“Second, studies of twins and siblings found that the IL-17RC promoter is hypomethylated in AMD patients [88], further suggesting the involvement of adaptive immunity and TH17 cells, as well as potential effect on macrophages.”
BackgroundLiu, B., Wei, L., Meyerle, C., Tuo, J., Sen, H. N., Li, Z., Chakrabarty, S., Agron, E., Chan, C.-C., Klein, M. L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-111 · Cited by 164 · cited 1×
“First, an intriguing increase in IL-22 and IL-17 levels in serum from AMD patients was shown, supported by the further finding that C5a stimulated IL-22 and IL-17 fromT cells [87].”
BackgroundCirculating anti-retinal antibodies as immune markers in age-related macular degeneration
Patel, N., Ohbayashi, M., Nugent, A. K., Ramchand, K., Toda, M., Chau, K., Bunce, C., Webster, A., Bird, A. C., Ono, S. J., et al. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02173.x · Cited by 125
Bora, N. S., Kaliappan, S., Jha, P., Xu, Q., Sohn, J.-H., Dhaulakhandi, D. B., Kaplan, H. J., & Bora, P. S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1872 · Cited by 124 · cited 1×
“Using knockout and specific inhibitor approaches, it appears that the alternative pathway of complement is the key driver of CNV, in that the removing of the classical or lectin pathway has no protective effect [61, 62].”
BackgroundCashman, S. M., Ramo, K., & Kumar-Singh, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019078 · Cited by 118 · cited 2×
“development of CNV, as CD59 mice lacking the MAC regulator CD59 develop CNV at a higher level than control mice [63], and treatment with recombinant soluble CD59aIgG2a fusion-protein [64] or gene therapy expressing soluble CD59 [65] both reduce CNV.”
BackgroundRohrer, B., Coughlin, B., Kunchithapautham, K., Long, Q., Tomlinson, S., Takahashi, K., & Holers, V. M. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.016 · Cited by 62
Self-citationBora, N. S., Jha, P., Lyzogubov, V. V., Kaliappan, S., Liu, J., Tytarenko, R. G., Fraser, D. A., Morgan, B. P., & Bora, P. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153130 · Cited by 53 · cited 1×
“development of CNV, as CD59 mice lacking the MAC regulator CD59 develop CNV at a higher level than control mice [63], and treatment with recombinant soluble CD59aIgG2a fusion-protein [64] or gene therapy expressing soluble CD59 [65] both reduce CNV.”
BackgroundCherepanoff, S., Mitchell, P., Wang, J. J., & Gillies, M. C. (2006) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2006.01281.x · Cited by 47
Cited by
Ferrington, D. A., Sinha, D., & Kaarniranta, K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.09.002 · Cited by 241
Self-citationClark, S. J., Schmidt, C. Q., White, A. M., Hakobyan, S., Morgan, B. P., & Bishop, P. N. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401613 · Cited by 122
The challenges and promise of complement therapeutics for ocular diseases
Park, D. H., Connor, K. M., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01007 · Cited by 108
Coughlin, B., Schnabolk, G., Joseph, K., Raikwar, H., Kunchithapautham, K., Johnson, K., Moore, K., Wang, Y., & Rohrer, B. (2016) · Scientific Reports · doi:10.1038/srep23794 · Cited by 65
Self-citation
Metadata
- Authors
- Whitcup, S. M., Sodhi, A., Atkinson, J. P., Holers, V. M., Sinha, D., Rohrer, B., & Dick, A. D.
- Venue
- International Journal of Inflammation
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-10
- ISSN
- 2042-0099 (ISSN-L)
- 2090-8040
- OpenAlex
- W2125619707
- Cited by
- 98
- References
- 38
- FWCI
- 15.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.